7 recruiting, 2 not yet recruiting, 1 unknown, 1 withdrawn. 11 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Recruiting 7, Not yet recruiting 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 4 | Recruiting 3, Withdrawn 1 |
Follow Simpson-Golabi-Behmel syndrome: new trials by email Literature Review of Simpson-Golabi-Behmel syndrome trials Research Report on Simpson-Golabi-Behmel syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs ACE723 - Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic | Phase 1 | Not yet recruiting | Acepodia Biotech, Inc. | 70 | 2026-11-01 | 2026-10-06 |
| GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT) 21.15.GPC3-CAR T Cells - Atypical Teratoid Rhabdoid Tumor, Central Nervous System Rhabdoid Tumor | Phase 1 | Not yet recruiting | Baylor College of Medicine | 21 | 2026-09-01 | 2026-04-07 |
| Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide - Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 30 | 2026-03-02 | 2026-03-30 |
| First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours AZD9793 Intravenous (IV) monotherapy, AZD9793 Subcutaneous (SC) monotherapy - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 304 | 2025-03-27 | 2026-10-14 |
| A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors AST-201 - Neoplasms, Carcinoma, Hepatocellular | Phase 1 | Recruiting | Aptamer Sciences, Inc. | 70 | 2025-03-11 | 2026-03-27 |
| A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors BGB-B2033, Tislelizumab, Bevacizumab - Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 630 | 2024-07-23 | 2026-09-16 |
| A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC MT-303, MT-303 +Atezolizumab + Bevacizumab - Hepatocellular Carcinoma | Phase 1 | Recruiting | Myeloid Therapeutics | 70 | 2024-07-01 | 2025-12-18 |
| A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment Codrituzumab - Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3) | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 50 | 2021-06-09 | 2026-10-26 |
| GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC CAR-T cell immunotherapy - Hepatocellular Carcinoma | Phase 1 | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 20 | 2019-10-05 | 2021-03-03 |
| GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression GPC3 and/or TGFβ targeting CAR-T cells - Hepatocellular Carcinoma, Immunotherapy | Phase 1 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 30 | 2017-07-01 | 2024-06-25 |
| CAR-T Cell Immunotherapy for HCC Targeting GPC3 CAR-T cell immunotherapy - GPC3 Positive Hepatocellular Carcinoma, CAR-T Cell Immunotherapy | Phase 1 / Phase 2 | Withdrawn | Fuda Cancer Hospital, Guangzhou | 2015-06-01 | 2020-07-16 |
Carcinoma, Hepatocellular (8) · Liver Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (1) · Hepatoblastoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Recurrence (1) · Rhabdoid Tumor (1)
Neoplasms (10) · Neoplasms by Histologic Type (10) · Digestive System Diseases (9) · Digestive System Neoplasms (9) · Liver Diseases (9) · Neoplasms by Site (9) · Adenocarcinoma (8) · Carcinoma (8) · Neoplasms, Glandular and Epithelial (8) · Liver Neoplasms (6) · Neoplasms, Complex and Mixed (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1)
Bevacizumab (2) · Immunotherapy, Adoptive (2) · Cyclophosphamide (1) · codrituzumab (1) · fludarabine (1) · tislelizumab (1)
Acepodia Biotech, Inc. (1) · Aptamer Sciences, Inc. (1) · AstraZeneca (1) · Baylor College of Medicine (1) · BeOne Medicines (1) · Beijing Biotech (1) · Fuda Cancer Hospital, Guangzhou (1) · Memorial Sloan Kettering Cancer Center (1) · Myeloid Therapeutics (1) · Second Affiliated Hospital of Guangzhou Medical University (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1)
China (7) · South Korea (4) · United States (4) · Japan (2) · Taiwan (2) · Australia (1) · Brazil (1) · France (1) · Hong Kong (1) · Italy (1) · New Zealand (1) · Puerto Rico (1) · Spain (1)
David Lee (1) · David Steffin, MD (1) · Jasia Mahdi, MD (1) · Lizhi Niu, PhD (1) · Matthew Maurer, MD (1) · Michael Ortiz, MD (1) · Zhenfeng Zhang, MD,PhD (1)
2025 (1)